GHENT, BELGIUM: Ardena, a prominent Contract Development and Manufacturing Organization (CDMO), has announced a significant leadership change. **Dr. Harry Christiaens** is retiring after two decades of service as CEO and will continue to serve on the company’s board. Succeeding him is **Jeremie Trochu**, a veteran in the pharmaceutical CDMO sector, who brings a wealth of experience from his tenure at Catalent, Inc., where he served as Division Head, Bioanalytics.
Under Dr. Christiaens’ leadership, Ardena transformed from a small consultancy in Ghent, Belgium, into a global CDMO powerhouse with over 500 employees and multiple European facilities. The company credits him with fostering growth that culminated in a recent €25 million investment in cutting-edge GMP nanomedicine and aseptic fill-finish capabilities.
Trochu’s appointment is met with enthusiasm by Ardena’s stakeholders, including **Alan MacKay** of GHO Capital, who expresses confidence in Trochu’s ability to drive international expansion and build upon the company’s success. Trochu himself is eager to lead Ardena’s agile team, emphasizing innovation and commitment to customer service.
Ardena’s mission remains steadfast: to expedite the development of new therapies by offering comprehensive services ranging from drug substance development to regulatory support, aiding pharmaceutical companies in bringing their products to clinical trials more efficiently.
The company looks forward to a new chapter of growth and innovation under Trochu’s leadership, as it continues to play a pivotal role in advancing drug development for the benefit of patients worldwide.
Leave a Reply